Peakdale extends its range of medicinal chemistry services
UK company Peakdale Molecular has extended its range of medicinal chemistry services with the addition of computer-aided drug design (CADD) tools that build on its core strength of innovative synthetic chemistry.
UK company Peakdale Molecular has extended its range of medicinal chemistry services with the addition of computer-aided drug design (CADD) tools that build on its core strength of innovative synthetic chemistry.
These services enable the company to provide compounds with a superior starting point for hit discovery, resulting in significant savings for subsequent optimisation. They are designed to complement its customers' drug discovery initiatives through hit-to-lead and lead optimisation projects, patent protection projects, back-up chemotypes and fast follower candidate programmes. They also include the synthesis of chemogenetic arrays on an exclusive basis utilising Peakdale's unique, privileged scaffolds.
The services are underpinned by Peakdale's strength in CADD, used to simulate drug-receptor interactions. The company's scientists are able to front-load compounds with beneficial ADMET properties and construct 3D-QSAR models to identify favourable regions of chemical space.
'The enhancement of our service offering, led by Dr Terry Hart, is a major step in the drive to further support our pharmaceutical and biotech customers' research and drug discovery programmes and marks a new chapter in the company's development,' said Kim Morrison, Peakdale ceo.